Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Inhibikase Therapeutics (IKT) EBITDA Margin (2020 - 2023)

Inhibikase Therapeutics (IKT) has disclosed EBITDA Margin for 4 consecutive years, with 440356600.0% as the latest value for Q4 2023.

  • On a quarterly basis, EBITDA Margin fell 44034978036.0% to 440356600.0% in Q4 2023 year-over-year; TTM through Sep 2024 was 2006393700.0%, a 200638757595.0% decrease, with the full-year FY2023 number at 7711.98%, up 697419.0% from a year prior.
  • EBITDA Margin was 440356600.0% for Q4 2023 at Inhibikase Therapeutics, down from 5773.14% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 186.56% in Q1 2021 to a low of 440356600.0% in Q4 2023.
  • A 4-year average of 27549245.84% and a median of 5550.6% in 2023 define the central range for EBITDA Margin.
  • Peak YoY movement for EBITDA Margin: soared 25251477bps in 2022, then plummeted 2000000000bps in 2023.
  • Inhibikase Therapeutics' EBITDA Margin stood at 704.66% in 2020, then tumbled by -36703bps to 259334.41% in 2021, then soared by 97bps to 6819.64% in 2022, then crashed by -6457080bps to 440356600.0% in 2023.
  • Per Business Quant, the three most recent readings for IKT's EBITDA Margin are 440356600.0% (Q4 2023), 5773.14% (Q3 2023), and 5328.07% (Q2 2023).